Trial testing copycat cancer drug withdrawn before starting
NCT ID NCT06884254
Summary
This study aimed to compare a new version of the cancer drug pertuzumab (called EG1206A) with the original version (Perjeta) for treating early-stage HER2-positive breast cancer. Patients would have received the drug along with standard chemotherapy and another targeted therapy before surgery. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Methodist Health System Clinical Research Institute
Dallas, Texas, 75023, United States
Conditions
Explore the condition pages connected to this study.